- 7th April, 10am BST - Prof Ann Ager, Cardiff University: 'T cell homing in cancer immunotherapy: challenges and opportunities'
- 21st April, 10am BST - Dr Luke Tattersall, University of Sheffield: ‘Preclinical bone cancer research’
- 27th April, 4pm BST - Prof Chris Bakal, Institute of Cancer Research: ‘The shape of you: Using AI, bioengineering, and statistical cell biology to understand how changes in cell morphogenesis drives cancer’
- 29th April, 4pm BST- Prof Dean Fennell, University of Leicester: ‘Mesothelioma. The evolving treatment landscape and future directions’
- How T cells detect and infiltrate solid cancers
- Arming T cells to improve homing and infiltration of solid cancers
- Cancer-associated blood vessels as an immune checkpoint during therapy
- Impact of HEV neogenesis in solid cancers on therapeutic outcomes
- Combined targeting of T cells and tumour blood vessels: a new approach to effective CAR T cell cancer therapy
Prof Ann Ager gained a PhD from Cambridge University studying inflammatory responses in vascular endothelial cells and trained in microvascular endothelial cell biology with Professor Judah Folkman at Harvard Medical School during her post-doctoral studies. In 1983 she moved to the Department of Immunology, University of Manchester as a postdoctoral fellow working with Professor Bill Ford and started what has become her life-long interests in specialised high endothelial venule (HEV) blood vessels and T-cell homing in health and disease.
She gained an MRC Senior Fellowship in Manchester before moving to a Principal Investigator position at the MRC National Institute for Medical Research, London in 1992 where she began working on L-selectin/CD62L. In 2007 she moved to the Division of Infection and Immunity, Cardiff University as a Reader and was awarded a personal chair in 2018. Since moving to Cardiff, her research has focused on T-cell trafficking in diseases such as virus infection, cancer, and Alzheimer’s disease.
Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.
Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.